CME: Advances in Treating HER2-Postive Metastatic Breast Cancer: Optimizing Pharmacotherapeutic Management Strategies
ACCREDITATION EXPIRED: February 25, 2023
Activity Description / Statement of Need:
In this online, self-learning activity:
Over a quarter million women and almost 2,700 men in the U.S. are diagnosed with breast cancer each year, and it is the second leading cause of cancer death in women. The prognosis associated with breast has improved in the last few decades due in large part to earlier detection. However, while detection at the loco-regional stage is associated with a five-year overall survival (OS) rate of 90%, patients with metastatic breast cancer (mBC) may expect five-year OS rates closer to 28%.
Because it is not curable, the goals of care in mBC are: palliation of symptoms, improvement of quality-of-life, and extension of survival. Hormone receptor positivity (HR+) in the absence of human epidermal growth factor receptor 2 overexpression (HER2+) has traditionally conferred a better prognosis. In contrast, HER2+ status is associated with a more negative prognosis, as it is associated with an increase in growth signals that are associated with accelerated tumor growth patterns, faster rates of recurrence, and higher mortality rates.
This activity has been designed to bring healthcare professionals’ knowledge of the rationale behind treatment of HER2+ mBC up to date and to improve their competence and performance in treating it.
Target Audience:
Medical oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with breast cancer.
Commercial Support Disclosure: This activity is supported by an educational grant from Seagen.
This activity is free of charge.
Release Date: February 25, 2022 -- Expiration Date: February 25, 2023
Faculty: Anees Chagpar, MD
Agenda
|
Introduction content: Cursory refresher and review of HER2+ mBC
|
|
|
Management of HER2+ mBC
· Treatment-naïve vs. experienced · HER2-directed therapy · HR+ · Treatment duration · Second- and later-line therapies
· Emerging therapies
|
|
Learning Objectives
By the end of the session the participant will be able to:
- Describe guideline-recommended therapy for HER2+ mBC.
- Recall first- and later-line pharmacotherapies for HER2+ mBC.
- Discuss investigational therapies for HER2+ mBC, their mechanisms of action, and their anticipated place in therapy.
- List the challenges and barriers to care associated with treating patients with HER2+ mBC.
- Formulate a treatment plan for a patient with HER2+ mBC.
Accreditation
ACCME Activity #201862208
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE ACTIVITY, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure:
Anees Chagpar, MD, Professor, Department of Surgery, Yale University School of Medicine, is on the Board of Directors for Protean Diagnostics; has received grant or research support from Lumicell; and has received financial compensation as a consultant and/or speaker from Sanofi Aventis, Novartis, Guardant Health, Lumicell, and Puma Diagnostics.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty will not discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This activity is supported by an educational grant from Seagen.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Hormone receptor-positive (HR+) advanced breast cancer: Where we are now and next steps
Biosimilars in the treatment of malignancies and supportive care
Treatment strategies for hepatocellular carcinoma (HCC): Now, it’s personal(ized)